Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 10/2020

Open Access 01-10-2020 | Review Article

Systematic review: non-adherence and non-persistence in intravitreal treatment

Authors: Christoph Ehlken, Focke Ziemssen, Nicole Eter, Ines Lanzl, Hakan Kaymak, Albrecht Lommatzsch, Alexander K. Schuster

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2020

Login to get access

Abstract

Purpose

Intravitreal injection of VEGF inhibitors has become the standard of care for different macular diseases within the last years resulting in improved visual outcomes. Under real-life conditions, however, the necessity for frequent retreatments and reexaminations poses a burden for patients and treatment centers. Non-adherence and non-persistence to intravitreal treatment may lead to inferior clinical outcomes, and knowledge of contributing factors is crucial to improve adherence. This systematic review analyzes current literature for potential factors involved in non-adherence and non-persistence.

Methods

A systematic search was conducted in PubMed and Embase including three different aspects of intravitreal injection therapy: (1) diseases with intravitreal injections as treatment, (2) intravitreal injection, and (3) aspects of therapy adherence or therapy persistence. Data from identified quantitative studies were further extracted and grouped according to WHO criteria (condition, socio-economy, therapy, patient, and health system). The methodological quality of identified studies was graded. Identified qualitative studies (i.e., interviews) were descriptively analyzed and their findings narratively reported.

Results

Twenty-four publications were included. In 16 of those publications, a quantitative data analysis was conducted, analyzing factors associated with non-adherence. Worse visual acuity at baseline and unfavorable development of visual acuity, higher age, and greater distance to the treatment center were associated with non-adherence, while there was inconsistent evidence for an association of comorbidity. In qualitative studies, high follow-up/treatment burden, fear and anxiety, disappointed patient expectations, and lack of motivation to continue treatment were reported as reasons for non-persistence.

Conclusions

Knowledge of potential barriers in IVT treatment may improve adherence and potentially clinical results. Improvements can be achieved particularly in the healthcare complex (organizational improvements) and the “patient” complex by establishing realistic expectations. Recurrent education of the patient may be necessary.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106–e116PubMed Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106–e116PubMed
2.
go back to reference Boyle J, Vukicevic M, Koklanis K et al (2018) Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 23:127–140PubMed Boyle J, Vukicevic M, Koklanis K et al (2018) Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 23:127–140PubMed
3.
go back to reference Group CR, Martin DF, Maguire MG et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908 Group CR, Martin DF, Maguire MG et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908
4.
go back to reference Investigators IS, Chakravarthy U, Harding SP et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411 Investigators IS, Chakravarthy U, Harding SP et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411
5.
go back to reference Freund KB, Korobelnik JF, Devenyi R et al (2015) Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489–1506PubMed Freund KB, Korobelnik JF, Devenyi R et al (2015) Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489–1506PubMed
6.
go back to reference Wykoff CC, Clark WL, Nielsen JS et al (2018) Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm 24:S3–S15PubMed Wykoff CC, Clark WL, Nielsen JS et al (2018) Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm 24:S3–S15PubMed
7.
go back to reference Holz FG, Tadayoni R, Beatty S et al (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623–1628PubMedPubMedCentral Holz FG, Tadayoni R, Beatty S et al (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623–1628PubMedPubMedCentral
8.
go back to reference Nguyen V, Daien V, Guymer R et al (2019) Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology 126:64–74PubMed Nguyen V, Daien V, Guymer R et al (2019) Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology 126:64–74PubMed
9.
go back to reference Framme C, Eter N, Hamacher T et al (2018) Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS. Ophthalmol Retina 2:539–549PubMed Framme C, Eter N, Hamacher T et al (2018) Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS. Ophthalmol Retina 2:539–549PubMed
11.
go back to reference Ahmed R, Aslani P (2014) What is patient adherence? A terminology overview. Int J Clin Pharm 36:4–7PubMed Ahmed R, Aslani P (2014) What is patient adherence? A terminology overview. Int J Clin Pharm 36:4–7PubMed
12.
go back to reference Frech S, Kreft D, Guthoff RF et al (2018) Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients-an observational cohort study. PLoS One 13:e0191185PubMedPubMedCentral Frech S, Kreft D, Guthoff RF et al (2018) Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients-an observational cohort study. PLoS One 13:e0191185PubMedPubMedCentral
13.
go back to reference Boulanger-Scemama E, Querques G, About F et al (2015) Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol 38:620–627PubMed Boulanger-Scemama E, Querques G, About F et al (2015) Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol 38:620–627PubMed
14.
go back to reference Droege KM, Muether PS, Hermann MM et al (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 251:1281–1284PubMed Droege KM, Muether PS, Hermann MM et al (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 251:1281–1284PubMed
15.
go back to reference Polat O, Inan S, Ozcan S et al (2017) Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol 47:205–210PubMedPubMedCentral Polat O, Inan S, Ozcan S et al (2017) Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol 47:205–210PubMedPubMedCentral
16.
go back to reference Weiss M, Sim DA, Herold T et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 38:2293–2300PubMed Weiss M, Sim DA, Herold T et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 38:2293–2300PubMed
17.
go back to reference Ehlken C, Helms M, Bohringer D et al (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13–20PubMed Ehlken C, Helms M, Bohringer D et al (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13–20PubMed
18.
go back to reference Sim PY, Gajree S, Dhillon B et al (2017) Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study. BMJ Open 7:e017771PubMedPubMedCentral Sim PY, Gajree S, Dhillon B et al (2017) Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study. BMJ Open 7:e017771PubMedPubMedCentral
19.
go back to reference Massamba N, Dirani A, Knoeri J et al (2015) Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab. Eye (Lond) 29:1453–1457 Massamba N, Dirani A, Knoeri J et al (2015) Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab. Eye (Lond) 29:1453–1457
20.
go back to reference Mueller S, Agostini H, Ehlken C et al (2016) Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology 123:876–883PubMed Mueller S, Agostini H, Ehlken C et al (2016) Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology 123:876–883PubMed
21.
go back to reference Vennedey V, Danner M, Evers SM et al (2016) Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients. Patient Prefer Adherence 10:993–1002PubMedPubMedCentral Vennedey V, Danner M, Evers SM et al (2016) Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients. Patient Prefer Adherence 10:993–1002PubMedPubMedCentral
22.
go back to reference Kim JH, Chang YS, Kim JW (2017) Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina 37:2254–2261PubMed Kim JH, Chang YS, Kim JW (2017) Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina 37:2254–2261PubMed
23.
go back to reference Wubben TJ, Johnson MW, Anti VTISG (2019) Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol 204:13–18PubMed Wubben TJ, Johnson MW, Anti VTISG (2019) Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol 204:13–18PubMed
24.
go back to reference Jandorf S, Krogh Nielsen M, Sorensen K et al (2019) Low health literacy levels in patients with chronic retinal disease. BMC Ophthalmol 19:174PubMedPubMedCentral Jandorf S, Krogh Nielsen M, Sorensen K et al (2019) Low health literacy levels in patients with chronic retinal disease. BMC Ophthalmol 19:174PubMedPubMedCentral
27.
go back to reference Alattas K (2016) Patients' tolerance of bimanual lid retraction versus a metal speculum for intravitreal injections. Clin Ophthalmol 10:1719–1721PubMedPubMedCentral Alattas K (2016) Patients' tolerance of bimanual lid retraction versus a metal speculum for intravitreal injections. Clin Ophthalmol 10:1719–1721PubMedPubMedCentral
28.
go back to reference Chua PY, Mitrut I, Armbrecht AM et al (2009) Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration. Arch Ophthalmol 127:939–940PubMed Chua PY, Mitrut I, Armbrecht AM et al (2009) Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration. Arch Ophthalmol 127:939–940PubMed
29.
go back to reference Cintra LP, Lucena LR, Da Silva JA et al (2009) Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging 40:13–18PubMed Cintra LP, Lucena LR, Da Silva JA et al (2009) Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging 40:13–18PubMed
30.
go back to reference Cohen SM, Billiris-Findlay K, Eichenbaum DA et al (2014) Topical lidocaine gel with and without subconjunctival lidocaine injection for intravitreal injection: a within-patient study. Ophthalmic Surg Lasers Imaging Retina 45:306–310PubMed Cohen SM, Billiris-Findlay K, Eichenbaum DA et al (2014) Topical lidocaine gel with and without subconjunctival lidocaine injection for intravitreal injection: a within-patient study. Ophthalmic Surg Lasers Imaging Retina 45:306–310PubMed
31.
go back to reference Guler M, Bilgin B, Capkin M et al (2015) Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean J Ophthalmol 29:190–194PubMedPubMedCentral Guler M, Bilgin B, Capkin M et al (2015) Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean J Ophthalmol 29:190–194PubMedPubMedCentral
32.
go back to reference Kaderli B, Avci R (2006) Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. Eur J Ophthalmol 16:718–721PubMed Kaderli B, Avci R (2006) Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. Eur J Ophthalmol 16:718–721PubMed
33.
go back to reference Kozak I, Cheng L, Freeman WR (2005) Lidocaine gel anesthesia for intravitreal drug administration. Retina 25:994–998PubMed Kozak I, Cheng L, Freeman WR (2005) Lidocaine gel anesthesia for intravitreal drug administration. Retina 25:994–998PubMed
34.
go back to reference Lagstein O, Ben-Artzi N, Achiron A et al (2017) Topical apraclonidine reduces pain after intravitreal injections: a double-blind randomized controlled trial. Retina 37:1575–1580PubMed Lagstein O, Ben-Artzi N, Achiron A et al (2017) Topical apraclonidine reduces pain after intravitreal injections: a double-blind randomized controlled trial. Retina 37:1575–1580PubMed
35.
go back to reference Makri OE, Tsapardoni FN, Plotas P et al (2018) Analgesic effect of topical nepafenac 0.1% on pain related to Intravitreal injections: a randomized crossover study. Curr Eye Res 43:1061–1064PubMed Makri OE, Tsapardoni FN, Plotas P et al (2018) Analgesic effect of topical nepafenac 0.1% on pain related to Intravitreal injections: a randomized crossover study. Curr Eye Res 43:1061–1064PubMed
36.
go back to reference Massamba N, Elluard M, Agoune W et al (2015) Assessment of ocular pain following ranibizumab intravitreal injection. Acta Ophthalmol 93:e231–e232PubMed Massamba N, Elluard M, Agoune W et al (2015) Assessment of ocular pain following ranibizumab intravitreal injection. Acta Ophthalmol 93:e231–e232PubMed
37.
go back to reference Moisseiev E, Regenbogen M, Rabinovitch T et al (2014) Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections. Eye (Lond) 28:980–985 Moisseiev E, Regenbogen M, Rabinovitch T et al (2014) Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections. Eye (Lond) 28:980–985
38.
go back to reference Rahimy E, Fineman MS, Regillo CD et al (2015) Speculum versus bimanual lid retraction during intravitreal injection. Ophthalmology 122:1729–1730PubMed Rahimy E, Fineman MS, Regillo CD et al (2015) Speculum versus bimanual lid retraction during intravitreal injection. Ophthalmology 122:1729–1730PubMed
39.
go back to reference Rifkin L, Schaal S (2012) Factors affecting patients' pain intensity during in office intravitreal injection procedure. Retina 32:696–700PubMed Rifkin L, Schaal S (2012) Factors affecting patients' pain intensity during in office intravitreal injection procedure. Retina 32:696–700PubMed
40.
go back to reference Sanabria MR, Montero JA, Losada MV et al (2013) Ocular pain after intravitreal injection. Curr Eye Res 38:278–282PubMed Sanabria MR, Montero JA, Losada MV et al (2013) Ocular pain after intravitreal injection. Curr Eye Res 38:278–282PubMed
41.
go back to reference Shiroma HF, Nunes RP, Farah ME et al (2014) Safety and efficacy of various concentrations of topical lidocaine gel for intravitreal injection. Expert Opin Drug Saf 13:1299–1303PubMed Shiroma HF, Nunes RP, Farah ME et al (2014) Safety and efficacy of various concentrations of topical lidocaine gel for intravitreal injection. Expert Opin Drug Saf 13:1299–1303PubMed
42.
go back to reference Tailor R, Beasley R, Yang Y et al (2011) Evaluation of patients' experiences at different stages of the intravitreal injection procedure - what can be improved? Clin Ophthalmol 5:1499–1502PubMedPubMedCentral Tailor R, Beasley R, Yang Y et al (2011) Evaluation of patients' experiences at different stages of the intravitreal injection procedure - what can be improved? Clin Ophthalmol 5:1499–1502PubMedPubMedCentral
43.
go back to reference Ulrich JN (2014) Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial. Retina 34:509–511PubMed Ulrich JN (2014) Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial. Retina 34:509–511PubMed
44.
go back to reference van Asten F, van Middendorp H, Verkerk S et al (2015) Are intravitreal injections with ultrathin 33-G needles less painful than the commonly used 30-G needles? Retina 35:1778–1785PubMed van Asten F, van Middendorp H, Verkerk S et al (2015) Are intravitreal injections with ultrathin 33-G needles less painful than the commonly used 30-G needles? Retina 35:1778–1785PubMed
45.
go back to reference Yau GL, Jackman CS, Hooper PL et al (2011) Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial. Am J Ophthalmol 151(333–337):e332 Yau GL, Jackman CS, Hooper PL et al (2011) Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial. Am J Ophthalmol 151(333–337):e332
46.
go back to reference Atchison EA, Omar AF, Iezzi R et al (2017) Outcomes of an Intravitreal injection clinic. Retina 37:1371–1376PubMed Atchison EA, Omar AF, Iezzi R et al (2017) Outcomes of an Intravitreal injection clinic. Retina 37:1371–1376PubMed
47.
go back to reference Curtis LH, Hammill BG, Qualls LG et al (2012) Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol 153(1116–1124):e1111 Curtis LH, Hammill BG, Qualls LG et al (2012) Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol 153(1116–1124):e1111
48.
go back to reference Ehlken C, Wilke T, Bauer-Steinhusen U et al (2018) Treatment of neovascular age-related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday practice: identification of health care constraints in Germany-the PONS study. Retina 38:1134–1144PubMed Ehlken C, Wilke T, Bauer-Steinhusen U et al (2018) Treatment of neovascular age-related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday practice: identification of health care constraints in Germany-the PONS study. Retina 38:1134–1144PubMed
49.
go back to reference Gillies MC, Nguyen V, Daien V et al (2016) Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology 123:2545–2553PubMed Gillies MC, Nguyen V, Daien V et al (2016) Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology 123:2545–2553PubMed
50.
go back to reference Heimes B, Gunnemann F, Ziegler M et al (2016) Compliance von Patienten mit altersabhängiger Makuladegeneration unter Anti-VEGF-Therapie - Analyse und Verbesserungsvorschläge. Ophthalmologe 113:925–932PubMed Heimes B, Gunnemann F, Ziegler M et al (2016) Compliance von Patienten mit altersabhängiger Makuladegeneration unter Anti-VEGF-Therapie - Analyse und Verbesserungsvorschläge. Ophthalmologe 113:925–932PubMed
51.
go back to reference Kruger Falk M, Kemp H, Sorensen TL (2013) Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 155(89–95):e83 Kruger Falk M, Kemp H, Sorensen TL (2013) Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 155(89–95):e83
52.
go back to reference McGrath LA, Lee LR (2013) Characteristics of patients who drop out from ranibizumab therapy. Asia Pac J Ophthalmol (Phila) 2:295–299 McGrath LA, Lee LR (2013) Characteristics of patients who drop out from ranibizumab therapy. Asia Pac J Ophthalmol (Phila) 2:295–299
53.
go back to reference Nunes RP, Nobrega MJ, De Novelli FJ et al (2010) Causes of interruption of bevacizumab therapy in age-related macular degeneration. Arq Bras Oftalmol 73:146–149PubMed Nunes RP, Nobrega MJ, De Novelli FJ et al (2010) Causes of interruption of bevacizumab therapy in age-related macular degeneration. Arq Bras Oftalmol 73:146–149PubMed
54.
go back to reference Oishi A, Mandai M, Nishida A et al (2011) Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol 21:777–782PubMed Oishi A, Mandai M, Nishida A et al (2011) Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol 21:777–782PubMed
55.
go back to reference Westborg I, Rosso A (2018) Risk factors for discontinuation of treatment for neovascular age-related macular degeneration. Ophthalmic Epidemiol 25:176–182PubMed Westborg I, Rosso A (2018) Risk factors for discontinuation of treatment for neovascular age-related macular degeneration. Ophthalmic Epidemiol 25:176–182PubMed
56.
go back to reference Ziemssen F, Eter N, Fauser S et al (2015) Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland - Behandlungsrealität von Ranibizumab bei nAMD in Deutschland. Ophthalmologe 112:246–254PubMed Ziemssen F, Eter N, Fauser S et al (2015) Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland - Behandlungsrealität von Ranibizumab bei nAMD in Deutschland. Ophthalmologe 112:246–254PubMed
57.
go back to reference Baxter JM, Fotheringham AJ, Foss AJ (2016) Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye (Lond) 30:698–704 Baxter JM, Fotheringham AJ, Foss AJ (2016) Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye (Lond) 30:698–704
58.
go back to reference Sii S, Aspinall P, Borooah S et al (2018) Exploring factors predicting changes in patients' expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration. Eye (Lond) 32:673–678 Sii S, Aspinall P, Borooah S et al (2018) Exploring factors predicting changes in patients' expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration. Eye (Lond) 32:673–678
59.
go back to reference Kostadinov F, Valmaggia C (2015) Disease perception in patients with wet age-related macular degeneration. Klin Monatsbl Augenheilkd 232:525–528PubMed Kostadinov F, Valmaggia C (2015) Disease perception in patients with wet age-related macular degeneration. Klin Monatsbl Augenheilkd 232:525–528PubMed
60.
go back to reference Droege KM, Caramoy A, Kersten A et al (2014) Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol 252:31–34PubMed Droege KM, Caramoy A, Kersten A et al (2014) Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol 252:31–34PubMed
61.
go back to reference Muller S, Ehlken C, Bauer-Steinhusen U et al (2017) Treatment of age-related neovascular macular degeneration: the patient's perspective. Graefes Arch Clin Exp Ophthalmol 255:2237–2246PubMedPubMedCentral Muller S, Ehlken C, Bauer-Steinhusen U et al (2017) Treatment of age-related neovascular macular degeneration: the patient's perspective. Graefes Arch Clin Exp Ophthalmol 255:2237–2246PubMedPubMedCentral
62.
go back to reference Senra H, Balaskas K, Mahmoodi N et al (2017) Experience of Anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol 177:213–224PubMed Senra H, Balaskas K, Mahmoodi N et al (2017) Experience of Anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol 177:213–224PubMed
63.
go back to reference van der Laan DM, Elders PJM, Boons C et al (2017) Factors associated with antihypertensive medication non-adherence: a systematic review. J Hum Hypertens 31:687–694PubMed van der Laan DM, Elders PJM, Boons C et al (2017) Factors associated with antihypertensive medication non-adherence: a systematic review. J Hum Hypertens 31:687–694PubMed
64.
go back to reference Bates TR, Connaughton VM, Watts GF (2009) Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 10:2973–2985PubMed Bates TR, Connaughton VM, Watts GF (2009) Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 10:2973–2985PubMed
65.
go back to reference Karimi S, Mosavi SA, Jadidi K et al (2019) Which quadrant is less painful for intravitreal injection? A prospective study. Eye (Lond) 33:304–312 Karimi S, Mosavi SA, Jadidi K et al (2019) Which quadrant is less painful for intravitreal injection? A prospective study. Eye (Lond) 33:304–312
66.
go back to reference Loureiro M, Matos R, Sepulveda P et al (2017) Intravitreal injections of bevacizumab: the impact of needle size in intraocular pressure and pain. J Curr Glaucoma Pract 11:38–41PubMedPubMedCentral Loureiro M, Matos R, Sepulveda P et al (2017) Intravitreal injections of bevacizumab: the impact of needle size in intraocular pressure and pain. J Curr Glaucoma Pract 11:38–41PubMedPubMedCentral
67.
go back to reference Gregori NZ, Weiss MJ, Goldhardt R et al (2012) Randomized clinical trial of two anesthetic techniques for intravitreal injections: 4% liquid lidocaine on cotton swabs versus 3.5% lidocaine gel. Expert Opin Drug Deliv 9:735–741PubMed Gregori NZ, Weiss MJ, Goldhardt R et al (2012) Randomized clinical trial of two anesthetic techniques for intravitreal injections: 4% liquid lidocaine on cotton swabs versus 3.5% lidocaine gel. Expert Opin Drug Deliv 9:735–741PubMed
68.
69.
go back to reference Faatz H, Rothaus K, Westhues D et al (2019) Treatment adherence and effectiveness of anti-vascular endothelial growth Faktor(VEGF) treatment of diabetic macular edema in the clinical routine : comparison between cooperative and unicentric organization of treatment. Ophthalmologe. https://doi.org/10.1007/s00347-019-00977-7 Faatz H, Rothaus K, Westhues D et al (2019) Treatment adherence and effectiveness of anti-vascular endothelial growth Faktor(VEGF) treatment of diabetic macular edema in the clinical routine : comparison between cooperative and unicentric organization of treatment. Ophthalmologe. https://​doi.​org/​10.​1007/​s00347-019-00977-7
70.
go back to reference Storey PP, Murchison AP, Pizzi LT et al (2016) Impact of physician communication on diabetic eye examination adherence: results from a retrospective cohort analysis. Retina 36:20–27PubMed Storey PP, Murchison AP, Pizzi LT et al (2016) Impact of physician communication on diabetic eye examination adherence: results from a retrospective cohort analysis. Retina 36:20–27PubMed
72.
go back to reference Kiss S, Chandwani HS, Cole AL et al (2016) Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clin Ophthalmol 10:2443–2453PubMedPubMedCentral Kiss S, Chandwani HS, Cole AL et al (2016) Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clin Ophthalmol 10:2443–2453PubMedPubMedCentral
73.
go back to reference Holz FG, Johnson KT, Bauer-Steinhusen U et al (2019) ANDROMEDA-an investigation of factors influencing the adherence of patients with neovascular age-related macular degeneration using the newly developed patient questionnaire LAF-IVT. Ophthalmologe. https://doi.org/10.1007/s00347-019-01005-4 Holz FG, Johnson KT, Bauer-Steinhusen U et al (2019) ANDROMEDA-an investigation of factors influencing the adherence of patients with neovascular age-related macular degeneration using the newly developed patient questionnaire LAF-IVT. Ophthalmologe. https://​doi.​org/​10.​1007/​s00347-019-01005-4
74.
go back to reference Bloch SB, Larsen M, Munch IC (2012) Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153(209–213):e202 Bloch SB, Larsen M, Munch IC (2012) Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153(209–213):e202
75.
go back to reference Kitano S, Sakamoto T, Goto R et al (2019) The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan. J Med Econ 22:254–265PubMed Kitano S, Sakamoto T, Goto R et al (2019) The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan. J Med Econ 22:254–265PubMed
76.
go back to reference Campbell JP, Bressler SB, Bressler NM (2012) Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 130:794–795PubMed Campbell JP, Bressler SB, Bressler NM (2012) Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 130:794–795PubMed
77.
go back to reference Claessen H, Genz J, Bertram B et al (2012) Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur J Epidemiol 27:519–524PubMed Claessen H, Genz J, Bertram B et al (2012) Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur J Epidemiol 27:519–524PubMed
Metadata
Title
Systematic review: non-adherence and non-persistence in intravitreal treatment
Authors
Christoph Ehlken
Focke Ziemssen
Nicole Eter
Ines Lanzl
Hakan Kaymak
Albrecht Lommatzsch
Alexander K. Schuster
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-020-04798-2

Other articles of this Issue 10/2020

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2020 Go to the issue